In 2015, the first phase 1 data on the safety of Ivosidenib in patients with advanced glioma and other IDH-mutant solid tumors was presented at the annual EORTC-NCI-AAR Molecular Targets and Cancer Therapeutics Symposium and indicated that Ivosidenib treatment was well-tolerated with a positive pharmacokinetic profile (ClinicalTrials.gov NCT02073994) (95). Here, IDH1 is linked to glioma.